Navigation Links
Newly Approved HIV Drug Shows Great Promise
Date:1/30/2008

Pricing Level Should Improve Access

WASHINGTON, Jan. 30 /PRNewswire/ -- The AIDS Institute, a national public policy research, advocacy, and education organization, is encouraged with the FDA's approval of the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) in nearly a decade. TMC125/etravirine was developed by Tibotec Pharmaceuticals, Ltd. and will be marketed in the U.S. by Tibotec Therapeutics as Intelence(R), a division of Ortho Biotech Products, L.P. The company announced introductory pricing for the new NNRTI at $21.80 per day, which is substantially lower than other recently introduced antiretrovirals.

In a Title II Community AIDS National Network release dated January 19, 2008, Dr. Donna Christian-Chistensen, Chair of the Congressional Black Caucus Health Brain Trust stated: "The efficacy that Intelence (TMC125/etravirine) has shown in the DUET studies is impressive. Intelence is an important new HIV medication that, for the first time, re-opens the NNRTI class to patients with NNRTI-resistant virus. We applaud Tibotec for its efforts to make this innovative new medication available and accessible to people living with HIV."

The U.S. Food and Drug Administration (FDA) granted accelerated approval to the anti-HIV medication. This is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced adult patients with HIV resistant to an NNRTI and other antiretroviral (ARV) agents. Intelence, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment- experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other ARV agents. This indication is based on Week 24 analyses from two randomized, double-blind, placebo-controlled trials of Intelence. Both studies were conducted in clinically advanced
'/>"/>

SOURCE The AIDS Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
7. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
8. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
9. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and LONDON , August 28, ... approach seamlessly connects people, ... improving outcomes and the cost ... PHG AEX: PHIA) today announced its presence at  ESC ... cardiology solutions, including Heart Model A.I. , EchoNavigator and IntelliSpace ...
(Date:8/27/2015)... CUPERTINO, Calif. , Aug. 27, 2015 ... management is scheduled to present at three upcoming healthcare ... , President and CEO, will present at the Rodman ... 10:00 a.m. Eastern time. The conference is being held ... York City . A live audio webcast of ...
(Date:8/27/2015)... Aug. 27, 2015  Eli Lilly and Company (NYSE: ... Healthcare Conference on Thursday, September 17, 2015. Sue ... Lilly Oncology and Richard Gaynor , M.D., senior ... Lilly Oncology, will participate in a fireside chat at ... live audio webcast will be available on the "Webcasts ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4DURECT to Participate in Upcoming Healthcare Conferences 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... Parkinson,s Disease, ... Decision Resources, WALTHAM, Mass., Aug. 13 Decision ... focusing on pharmaceutical and,healthcare issues, finds that 61 percent ... drug treatment in the first year of,diagnosis. According to ...
... VIENNA, Va., Aug. 14 CEL-SCI CORPORATION,(Amex: ... an agreement with a,biomedical real estate group under which ... for its cancer drug Multikine(R). The,financial value of this ... located near Baltimore, Maryland. Once fully built out to ...
Cached Medicine Technology:Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis 2Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 2CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 4
(Date:8/30/2015)... ... August 31, 2015 , ... Avid collector Andrew Hawley ... Doors Shrine Auditorium concert posters. This hand colored artwork is one of the most ... Los Angles. Hawley states, "When the doors played the Shrine, the band was ...
(Date:8/30/2015)... ... August 31, 2015 , ... ChopChop Kids, the nonprofit publisher ... recently elected two new officers to serve on the organization’s Board of Directors ... and teaching kids to cook real food with their families and help continue ...
(Date:8/30/2015)... ... August 30, 2015 , ... Scientists in France say asbestos exposure ... of digestive cancers. Surviving Mesothelioma has just posted an article on the new research. ... Caen measured the cancer incidence among 2,024 French asbestos plant workers from 1978 to ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( ... to Executive Assistant to CEO Mitch Gould for Nutritional Products International. Through ... goals. Kathleen graduated from Florida State University with a Bachelor of Science ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
Breaking Medicine News(10 mins):Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2
... likely woman was first infected with dangerous germ, , , WEDNESDAY, ... their food and more with their pets, but one thing ... is a drug-resistant staph infection. , However, according to a ... England Journal of Medicine , a German family appears to ...
... Public Understanding of a,21st Century Epidemic, ... of the,population, experts warn that Alzheimer,s disease ... and unsustainable burdens in,terms of health care ... lost to a devastating disease., (Photo: ...
... 2008, LANCASTER, Pa., March 12 Herley Industries,Inc. ... the second quarter,ended February 3, 2008., Net sales ... $34.7 million. Net loss for the period was approximately ... Company,s Chairman and CEO, will host a conference call,on ...
... 3 and Turmeric ... Supplement, LEXINGTON, ... the latest addition to their family of joint,relief products, which can be ... formula containing Omega 3 and,Turmeric for double strength joint relief., Over ...
... Caregivers were stressed, ate poorly, study found , , WEDNESDAY, March ... serious heart problem may raise your own risk of cardiac ... than 500 family members and others caring for a heart ... of the time were more likely to show psychological strain ...
... novel aerosol version of the most common tuberculosis ... an oral mist, offers significantly better protection against ... dose of the traditional injected vaccine, researchers report ... Academy of Sciences. , The aerosol vaccine -- ...
Cached Medicine News:Health News:Woman and Cat Shared 'Super Bug' 2Health News:Woman and Cat Shared 'Super Bug' 3Health News:New Tools Boost Alzheimer's Awareness 2Health News:New Tools Boost Alzheimer's Awareness 3Health News:Herley Reports Second Quarter Results 2Health News:Herley Reports Second Quarter Results 3Health News:Herley Reports Second Quarter Results 4Health News:Herley Reports Second Quarter Results 5Health News:Herley Reports Second Quarter Results 6Health News:Herley Reports Second Quarter Results 7Health News:Herley Reports Second Quarter Results 8Health News:Herley Reports Second Quarter Results 9Health News:Herley Reports Second Quarter Results 10Health News:The Makers of Conquer HA(TM) Launch All-Natural Double Strength Anti- Inflammatory Formula 2Health News:Caring for Heart Patients Can Strain Hearts 2Health News:Caring for Heart Patients Can Strain Hearts 3Health News:Inhaled tuberculosis vaccine more effective than traditional shot 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... a monopolar cautery connector extending from the ... used for electrosurgery when properly attached to ... ,Ethicon Endo-Surgery provides disposable handheld instruments ... Our handheld instruments come in 5mm and ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: